Compare, Analyse JUBILANT LIFE SCIENCES with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 JUBILANT LIFE SCIENCES   MYLAN
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
MYLAN
Dec-18
JUBILANT LIFE SCIENCES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs8983,589-   
Low Rs6181,975-   
Sales per share (Unadj.) Rs572.01,651.5-  
Earnings per share (Unadj.) Rs36.244.8-  
Cash flow per share (Unadj.) Rs59.5354.1-  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs301.91,786.6-  
Shares outstanding (eoy) m159.28514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.7 78.6%   
Avg P/E ratio x20.962.0 33.7%  
P/CF ratio (eoy) x12.77.9 162.0%  
Price / Book Value ratio x2.51.6 161.2%  
Dividend payout %12.40-   
Avg Mkt Cap Rs m120,6941,431,473 8.4%   
No. of employees `0002.435.0 6.8%   
Total wages/salary Rs m19,2600-   
Avg. sales/employee Rs Th38,120.624,276.6 157.0%   
Avg. wages/employee Rs Th8,058.40-   
Avg. net profit/employee Rs Th2,414.3659.2 366.2%   
INCOME DATA
Net Sales Rs m91,108849,683 10.7%  
Other income Rs m3570-   
Total revenues Rs m91,466849,683 10.8%   
Gross profit Rs m17,390219,866 7.9%  
Depreciation Rs m3,709159,094 2.3%   
Interest Rs m2,19840,867 5.4%   
Profit before tax Rs m11,84019,906 59.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,268-3,167 -103.2%   
Profit after tax Rs m5,77023,072 25.0%  
Gross profit margin %19.125.9 73.8%  
Effective tax rate %27.6-15.9 -173.5%   
Net profit margin %6.32.7 233.2%  
BALANCE SHEET DATA
Current assets Rs m45,848474,462 9.7%   
Current liabilities Rs m20,897345,935 6.0%   
Net working cap to sales %27.415.1 181.0%  
Current ratio x2.21.4 160.0%  
Inventory Days Days5784 68.0%  
Debtors Days Days5193 54.6%  
Net fixed assets Rs m65,498164,824 39.7%   
Share capital Rs m159452 35.2%   
"Free" reserves Rs m47,9300-   
Net worth Rs m48,089919,201 5.2%   
Long term debt Rs m42,429992,113 4.3%   
Total assets Rs m114,6852,465,655 4.7%  
Interest coverage x6.41.5 429.5%   
Debt to equity ratio x0.91.1 81.7%  
Sales to assets ratio x0.80.3 230.5%   
Return on assets %6.92.6 267.9%  
Return on equity %12.02.5 478.0%  
Return on capital %12.43.2 390.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-4,8050-   
CASH FLOW
From Operations Rs m11,215176,564 6.4%  
From Investments Rs m-10,118-91,264 11.1%  
From Financial Activity Rs m6,574-82,254 -8.0%  
Net Cashflow Rs m7,6121,463 520.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 75.4 Rs / USD

Compare JUBILANT LIFE SCIENCES With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare JUBILANT LIFE SCIENCES With: PROCTER & GAMBLE HEALTH  AUROBINDO PHARMA  WOCKHARDT  FRESENIUS KABI ONCO.  SANOFI INDIA  



Today's Market

Sensex Tanks 1,375 Points; Nifty Ends Below 8,300 Mark(Closing)

Indian share markets witnessed selling pressure throughout the day and ended deep in the red with Sensex and Nifty witnessing a sharp fall during closing hours.

Related Views On News

JUBILANT LIFE SCIENCES Plunges by 8%; BSE 500 Index Down 1.7% (Market Updates)

Mar 30, 2020 | Updated on Mar 30, 2020

JUBILANT LIFE SCIENCES share price has plunged by 8% and its current market price is Rs 260. The BSE 500 is down by 1.7%. The top gainers in the BSE 500 Index are E.I.D. PARRY (up 12.5%) and BALRAMPUR CHINI (up 10.0%). The top losers are JUBILANT LIFE SCIENCES (down 8.3%) and EICHER MOTOR (down 5.4%).

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus (Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It. (Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World (The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

How to Trade the Coronavirus Crash - Download this FREE Report Now
How to Profit Even During These Times of Crisis: Vijay Bhambwani Reveals his Strategy...
The Best Stocks For 2020 - How to Spot Multibagger Ideas. FREE Sign up!
Free Report: The Secret to Increasing Your Trading Profits Daily!
Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!

JUBILANT LIFE SCIENCES SHARE PRICE


Mar 30, 2020 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

OTHER USEFUL LINKS

MARKET STATS